James Murdoch has been appointed a non-executive director at the pharmaceutical company GlaxoSmithKline.
Murdoch, the chairman and chief executive of News Corporation Europe and Asia, and chairman of BSkyB, starts in the £75,000-a-year post on 20 May.
He will serve as a member of GSK's corporate responsibility committee, where he will help to review "external issues that might have the potential for serious impact upon the group's business and reputation".
"I am delighted to welcome James to the board of GSK," said Glaxo's chairman, Sir Christopher Gent, the former Vodafone chief executive. "His experience of global business, marketing and communications will bring a unique and alternative perspective to the board.
"He will also be an excellent addition to the board's corporate responsibility committee, an area where he has shown particular leadership at BSkyB and News Corporation."
Murdoch's fellow directors will include the outgoing Reed Elsevier chief executive Sir Crispin Davis and Sir Robert Wilson, the non-executive chairman of the Economist Group.
Murdoch, the son of the media mogul Rupert Murdoch, also sits on the boards of Yankee Global Enterprises, the parent company of the New York Yankees baseball club, and the Harvard Lampoon, a US student magazine. He is on the leadership council of the Climate Group, an independent organisation focused on tackling climate change.